Modified stem cells protect healthy tissue from brain cancer treatment

Share this article:

Drug treatment for glioblastoma may be made more effective by introducing a chemotherapy-resistant gene into normal bone marrow stem cells to protect them from the toxic effects of chemotherapy.

Median survival for persons with glioblastoma is just 12 to 15 months, in part because there is no cure for the disease but also because the treatment that does exist cannot be used effectively: The temozolomide chemotherapy regimen has to be accompanied by benzylguanine, because the second drug counteracts the chemotherapy-resistant gene MGMT. Glioblastoma cells produce a large amount of MGMT, but the protein is also present in normal blood and bone marrow cells. Benzylguanine disables MGMT in both diseased and healthy cells, making both susceptible to the harmful effects of treatment. This means chemotherapy cannot be administered to the desired extent.

However, researchers at the Fred Hutchinson Cancer Research Center in Seattle, Washington, recently reported encouraging results from a clinical trial involving four persons with glioblastoma. In the trial, patients' bone marrow stem cells were removed and modified with a retrovirus vector to keep them chemotherapy-resistant in the face of benzylguanine administration. The cells were then reinfused into the patients.

The gene-modified stem cells persisted for more than a year, with patients suffering no apparent harmful effects.

“Our initial results are encouraging because our first patient is still alive and without evidence of disease progression almost 2 years after diagnosis,” noted investigator Hans-Peter Kiem, MD, in a statement describing his team's findings, which were presented at the annual meeting of the American Society of Gene and Cell Therapy, held May 18-21, 2011, in Seattle.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.